ZAP-70 intron1 DNA methylation status: Determination by pyrosequencing in B chronic lymphocytic leukemia

被引：19

作者：

Chantepie, Sylvain P. ^{[1
,2
,3
]}

Vaur, Dominique ^{[2
,3
]}

Grunau, Christoph ^{[4
]}

Salauen, Veronique ^{[5
]}

Briand, Melanie ^{[2
]}

Parienti, Jean-Jacques ^{[6
]}

Heutte, Natacha ^{[2
]}

Cheze, Stephane

Roussel, Mikel ^{[7
]}

Gauduchon, Pascal ^{[2
]}

Leporrier, Michel

Krieger, Sophie ^{[2
,3
]}

机构：

[1] Univ Caen Basse Normandie, Hematol Serv, CHU Caen, Hematol Clin, F-14033 Caen, France

[2] Univ Caen Basse Normandie, Ctr Francois Baclesse, GRECAN, F-14033 Caen, France

[3] Univ Caen Basse Normandie, Ctr Francois Baclesse, Lab Biol Clin & Oncol, F-14033 Caen, France

[4] CNRS, UMR 5244, Pergpignan, France

[5] CHU Caen, Hematol Lab, F-14000 Caen, France

[6] CHU Caen, Serv Rech Clin & Biostat, F-14000 Caen, France

[7] CHU Pontchaillou Rennes, Hematol Lab, Rennes, France

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 06期

关键词：

ZAP-70; CLL; DNA methylation; Pyrosequencing; Epigenetics; VARIABLE-REGION MUTATIONS; EXPRESSION; DISEASE; CD38; PHENOTYPE; SURVIVAL; REVEALS; CANCER; GENES; CELLS;

D O I：

10.1016/j.leukres.2009.10.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ZAP-70 expression is a strong prognostic indicator in chronic lymphocytic leukemia. However, ZAP-70 quanti. cation by flow cytometry lacks sufficient standardization. Based upon the correlation between ZAP-70 expression and its gene methylation status, we have developed a quantitative pyrosequencing assay for the determination of ZAP-70 methylation adapted for routine use. Methylation in four CpG pairs (C-223, C-243, C-254, and C-267) in the first intron of ZAP-70 is associated with repression of ZAP-70. Moreover, it correlates with CD38 expression (n = 111, p<.0001), IgHv mutation status (n = 106, p<.0001), time to treatment (p<.0001), and overall survival (p=.0014). Pyrosequencing of ZAP-70 provides a good alternative to flow cytometry. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：800 / 808

页数：9

共 38 条

[31] ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
Rassenti, LZ
Huynh, L
Toy, TL
Chen, L
Keating, MJ
Gribben, JG
Neuberg, DS
Flinn, IW
Rai, KR
Byrd, JC
Kay, NE
Greaves, A
Weiss, A
Kipps, TJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (09) : 893 - 901
[32] ZAP-70 mRNA expression provides clinically valuable information in early-stage chronic lymphocytic leukemia
Reinoso-Martin, Cristina
Jantus-Lewintre, Eloisa
Garcia Ballesteros, Carlos
Benet Campos, Carmen
Mayans Ferrer, Jose Ramon
Garcia-Conde, Javier
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (09): : 1422 - 1424
[33] Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia
Rosenwald, A
Alizadeh, AA
Widhopf, G
Simon, R
Davis, RE
Yu, X
Yang, LM
Pickeral, OK
Rassenti, LZ
Powell, J
Botstein, D
Byrd, JC
Grever, MR
Cheson, BD
Chiorazzi, N
Wilson, WH
Kipps, TJ
Brown, PO
Staudt, LM
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (11) : 1639 - 1647
[34] ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage
Scielzo, C
Camporeale, A
Geuna, M
Alessio, M
Poggi, A
Zocchi, MR
Chilosi, M
Caligaris-Cappio, F
Ghia, P
[J]. LEUKEMIA, 2006, 20 (04) : 689 - 695
[35] Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA
Stamatopoulos, Basile
Haibe-Kains, Benjamin
Equeter, Carole
Meuleman, Nathalie
Soree, Anne
De Bruyn, Cecile
Hanosset, Delphine
Bron, Dominique
Martiat, Philippe
Lagneaux, Laurence
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (06): : 790 - 799
[36] The cancer epigenome - components and functional correlates
Ting, Angela H.
McGarvey, Kelly M.
Baylin, Stephen B.
[J]. GENES & DEVELOPMENT, 2006, 20 (23) : 3215 - 3231
[37] Tost Jorg, 2007, V373, P89
[38] ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile
Wiestner, A
Rosenwald, A
Barry, TS
Wright, G
Davis, RE
Henrickson, SE
Zhao, H
Ibbotson, RE
Orchard, JA
Davis, Z
Stetler-Stevenson, M
Raffeld, M
Arthur, DC
Marti, GE
Wilson, WH
Hamblin, TJ
Oscier, DG
Staudt, LM
[J]. BLOOD, 2003, 101 (12) : 4944 - 4951

← 1 2 3 4 →